Follow The Filings

NEO Neogenomics Inc.

Health Care, filed as NEOGENOMICS INC (COM NEW), Equity Among managers we track Quote on Google Finance, opens in a new tab

No current holdings among managers we track for this security. See ownership history or the ownership grid, activity, or search.

Insider trades

Open-market buys and sales by NEO's executives, directors and 10% owners in the last 12 months, from their Form 4s

All NEO insider trades
  • None no insider bought on the open market
  • $321K sold by 1 insider outside a trading plan
  • $646K sold by 3 insiders under 10b5-1 plans
  1. Greg D. Aunan Chief Accounting Officer
    Sale
    $321K 20,000 shares at $16.07 80% of stake
    Traded Aug 4 Filed Aug 6
  2. Lynn A. Tetrault Director
    Planned sale
    $59K 5,307 shares at $11.10 5.8% of stake
    Traded Jun 15 Filed Jun 17
  3. Lynn A. Tetrault Director
    Planned sale
    $60K 5,307 shares at $11.29 5.5% of stake
    Traded Jun 9 Filed Jun 11
  4. Warren Stone COO
    Planned sale
    $277K 22,128 shares at $12.50 15% of stake
    Traded Jan 20 Filed Jan 21
  5. Alicia C. Olivo EVP, GC & Business Development
    Planned sale
    $251K 20,916 shares at $12.00 40% of stake
    Traded Nov 25, 2025 Filed Nov 28, 2025
  6. Alicia C. Olivo EVP, GC & Business Development
    Planned sale
    $49K 4,918 shares at $10.00 10% of stake
    Traded Oct 16, 2025 Filed Oct 20, 2025

Also filed in the last 12 months, not counted as buying or selling: 26 option exercises and 22 share withholdings for taxes.

Congress

1 member of Congress traded NEO in the last three years: 2 buys and 0 sales. 2 members listed it in 2025 annual reports.

All Congress trades
  1. Gilbert Ray Cisneros, Jr. D-CA-31 Buy $1K–$15K Aug 7 filed Sep 10
  2. Gilbert Ray Cisneros, Jr. D-CA-31 Buy $1K–$15K May 7, 2025 filed Jun 6, 2025

SEC filings

Recent issuer filings from EDGAR, 20 shown.

Filed Form Detail Links
SCHEDULE 13G/A —
10-Q
8-K 2.02,9.01
8-K 2.02,5.02,5.03,9.01
SCHEDULE 13G/A —
8-K 5.02
SCHEDULE 13G —
SCHEDULE 13G/A —
8-K 2.02,9.01
10-Q
8-K/A 7.01,8.01,9.01
8-K 7.01,8.01,9.01
8-K 5.02,7.01,9.01
8-K 1.01,2.03,3.02,8.01,9.01
8-K 8.01,9.01
8-K 8.01,9.01
8-K 5.02,5.07,9.01
SCHEDULE 13G/A —
SCHEDULE 13G/A —
SCHEDULE 13G/A —

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $591.64M $660.57M $727.33M
Gross profit $244.6M $290.1M $314.29M
Gross margin * 41.3% 43.9% 43.2%
Net income -$87.97M -$78.73M -$108.02M
Net margin * -14.9% -11.9% -14.9%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $596.81M $596.02M $376.29M
Total non-current assets $1.08B $1.04B $0.984B
Total assets $1.68B $1.64B $1.36B
Total current liabilities $96.3M $301.24M $88.3M
Total non-current liabilities $643.39M $434.46M $434.97M
Total equity $941.54M $902.34M $836.56M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$1.95M $7.02M $5.23M
Cash from investing $76.71M $12.86M -$12.34M
Cash from financing $4.55M $4.65M -$200.29M
Net change in cash * $79.31M $24.52M -$207.39M

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.

Further reading

As an Amazon Associate, FollowTheFilings earns from qualifying purchases.

More on the shelf